Nutritional supplements firm GNC has reached a deal with the New York State attorney general's office to do more stringent testing of ingredients in its products, including the use of genetic testing. 

In a statement on Monday, GNC emphasizes that all of its relevant products were in compliance with the Food and Drug Administration's "Current Good Manufacturing Practices" and are "safe, pure, properly labeled and in full compliance with all regulatory requirements." 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.